Amylin-Based Pharmacotherapy – Past, Present & Future
Jonathan D. Roth(Rutgers, The State University of New Jersey), David G. Parkes(Amplyx Pharmaceuticals (United States)), Christine M. Mack, Soumitra S. Ghosh(Amplyx Pharmaceuticals (United States))
Immunology Endocrine & Metabolic Agents - Medicinal Chemistry
December 1, 2008
Cited by 15
Related Papers
Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies
|Proceedings of the National Academy of Sciences|2008|433
Amylin: Pharmacology, Physiology, and Clinical Potential
|Pharmacological Reviews|2015|395
Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment
|American Journal of Physiology-Gastrointestinal and Liver Physiology|2013|294
Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice
|American Journal of Physiology-Gastrointestinal and Liver Physiology|2012|278